COMP <GO>
MLTX vs SVRA // EV/EBITDA & P/E VALUATION
MoonLake Immunotherapeutics (Class A) (NASDAQ) VS. Savara Inc. (NASDAQ) • 15-METRIC TALLY: MLTX 2
— SVRA 2
■ METRIC PARITY
LAST: $12.57 (+2.11%) • MKT CAP: $1.07B
valuation
—
LAST: $4.95 (-1.39%) • MKT CAP: $1.02B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MLTX VS. SVRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MLTX | SVRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.33% | -9.94% | -8.39 | SVRA | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | SVRA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 52.5 | +4.70 | MLTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.07B | $1.02B | $52.8M | MLTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MLTX REV | SVRA REV | MLTX GROSS % | SVRA GROSS % | MLTX FCF | SVRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$196.0M | -$101.1M |
| FY 2024 | $0 | $0 | — | — | -$117.1M | -$89.1M |
| FY 2023 | $0 | $0 | — | — | -$42.8M | -$51.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MLTX // BETA —
SVRA // BETA —